Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats

Neurotoxicology and Teratology

Volumn 29, Issue 1, 2007, Pages 96-107

  LaRoche, Ronee B ^a   Morgan, Russell E ^a  

^a WESTERN ILLINOIS UNIVERSITY   (United States)

Author keywords

Adolescent; Attention; Behavior; Development; Fluoxetine; Postnatal; SSRI

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; MAZE TEST; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; REACTION TIME; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; VISUAL DISCRIMINATION;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ATTENTION; BEHAVIOR, ANIMAL; BODY WEIGHT; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; FLUOXETINE; MALE; MAZE LEARNING; PHOTIC STIMULATION; RATS; RATS, LONG-EVANS; REACTION TIME; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; VISUAL PERCEPTION;

MALUS X DOMESTICA; RATTUS;

EID: 33846786700     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2006.11.008     Document Type: Article

References (47)

1. Alonso S.J., Castellano M.A., Afonso D., and Rodriguez M. Effects of maternal stress during pregnancy on forced swimming test behavior of the offspring. Physiol. Behav. 49 (1991) 69-72
2. Ansorge M.S., Zhou M., Lira A., Hen R., and Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306 (2004) 879-881
3. Bastos E.F., deSouza Marcelino J.L., Amaral A.R., and Serfaty C.A. Fluoxetine-induced plasticity in the rodent visual system. Brain Res. 824 (1999) 28-35
4. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100 (1990) 509-514
5. Carlsson M., and Carlsson A. In vivo evidence for a greater brain tryptophan hydroxylase capacity in female than in male rats. Arch. Pharmacol. 338 (1988) 345-349
6. Choi H.K., and Waxman D.J. Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrine 141 (2000) 3245-3255
7. Committee on Safety of Medicines. Selective serotonin reuptake inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data (2004). http://medicines.mhra.gov.uk/ourwork/monitorsafetyqualmed/safetymessages/ssrioverview%5F101203.htm http://medicines.mhra.gov.uk/ ourwork/monitorsafetyqualmed/safetymessages/ssrioverview%5F101203.htm
8. Devane C.L. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum. Psychopharmacol.: Clin. Exp. 10 (2004) 185-193
9. Dhir R.N., Dworakowski W., Thangavel C., and Shapiro B.H. Sexually dimorphic regulation of hepatic isoforms of human cytochrome P450 by growth hormone. J. Pharmacol. Exp. Ther. 316 (2006) 87-94
10. Doremus T.L., Varlinskaya E.I., and Spear L.P. Factor analysis of elevated plus-maze behavior in adolescent and adult rats. Pharmacol. Biochem. Behav. 83 (2006) 570-577
11. Dow-Edwards D.L. Modification of acoustic startle reactivity by cocaine administration during the postnatal period: comparison with a specific serotonin reuptake inhibitor. Neurotoxicol. Teratol. 18 (1996) 289-296
12. El-Masry S.e.-D., Cohen G.M., and Mannering G.J. Sex-dependent differences in drug metabolism in the rat. I. temporal changes in microsomal drug-metabolizing system of the liver during sexual maturation. Drug Metab. Dispos. 2 (1974) 267-278
13. Garland E.J. Facing the evidence: antidepressant treatment in children and adolescents. Can. Med. Assoc. J. 170 (2004) 489-491
14. Haleem D.J., Kennett G.A., and Curzon G. Hippocampal 5-hydroxytryptamine synthesis is greater in female rats than in males and more decreased by the 5-HT1A agonist 8-OH-DPAT. J. Neural Transm. 79 (1990) 93-101
15. Hanson H.H., Sanchez C., and Meier E. Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression?. J. Pharmacol. Exp. Ther. 283 (1997) 1333-1341
16. Hilakivi L.A., and Hilakivi I.T. Increased adult behavioral "despair" in rats neonatally exposed to desipraimine or zimeldine: an animal model of depression?. Pharmacol. Biochem. Behav. 28 (1987) 367-369
17. Hilakivi L.A., Sinclair J.D., and Hilakivi I.T. Effects of neonatal treatment with clomipramine on adult ethanol related behavior in the rat. Brain Res. 317 (1984) 129-132
18. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54 (1996) 21-30
19. Jones M.D., and Lucki I. Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. Neuropsychopharmacology 30 (2005) 1039-1047
20. Jureidini J.N., Doeke C.J., Mansfield P.R., Haby M.M., Menkes D.B., and Tonkin A.L. Efficacy and safety of antidepressants for children and adolescents. Br. Med. J. 328 (2004) 879-883
21. Khan A., Brodhead A.E., Schwartz K.A., Kolts R.L., and Brown W.A. Sex differences in antidepressant response in recent antidepressant clinical trials. J. Clin. Psychopharmacol. 25 (2005) 318-324
22. Kinney G.G., Vogel G.W., and Feng P. Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomiprimine treatment: implications for endogenous depression. Brain Res. 756 (1997) 68-75
23. Kornstein S.G., Schatzberg A.F., Thase M.E., Yonkers K.A., McCollough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., and Keller M.B. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatr. 157 (2000) 1445-1452
24. Lifschytz T., Shalom G., Lerer B., and Newman M.E. Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats. Eur. Neuropsychopharmacol. 16 (2006) 115-121
25. Maciag D., Simpson K.L., Coppinger D., Lu Y., Wang Y., Lin R.C.S., and Paul I.A. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31 (2006) 47-57
26. McEwen B.S., Alves S.E., Bulloch K., and Weiland N.G. Clinically relevant basic science studies of gender differences and sex hormone effects. Psychopharmacol. Bull. 34 (1998) 251-259
27. Monleón S., Urquiza A., Arenas M.C., Vinader-Caerols C., and Parra A. Chronic administration of fluoxetine impairs inhibitory avoidance in male but not female mice. Behav. Brain Res. 136 (2006) 483-488
28. Morgan R.E., Garavan H.P., Smith E.G., Driscoll L.L., Levitsky D.A., and Strupp B.J. Early lead exposure produces lasting changes in sustained attention, response initiation, and reactivity to errors. Neurotoxicol. Teratol. 23 (2001) 519-531
29. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc. Natl. Acad. Sci. 94 (1997) 5308-5313
30. Norrholm S.D., and Ouimet C.C. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus. Brain Res. 883 (2000) 205-215
31. NTP-CERHR. National Toxicology Program - Center for the evaluation of risks to human reproduction expert panel report on the reproductive and developmental toxicity of fluoxetine (2004). http://cerhr.niehs.nih.gov
32. Odell W.D. Sexual maturation in the rat. In: Grumbach M.M., Sizonenko P.C., and Aubert M.L. (Eds). Control of the onset of puberty (1990), Williams and Wilkins, Baltimore, MD 183-210
33. Ojeda S.R., and Urbanski H.F. Puberty in the rat. In: Knobil E., and Neill J.D. (Eds). The physiology of reproduction. 2nd ed. (1994), Raven Press, New York, NY 363-409
34. Shapiro B.H., Arun A.K., and Nisar P.A. Gender differences in drug metabolism regulated by growth hormone. Int. J. Biochem. Cell Biol. 27 (1995) 9-20
35. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24 (2000) 417-463
36. Spear L.P. Adolescent brain development and animal models. Ann. N.Y. Acad. Sci. 1021 (2004) 23-26
37. United States Food and Drug Administration. FDA approves Prozac for pediatric use to treat depression and OCD. FDA Talk Paper, T03-01 (Jan 2003). http://www.fds.gov/bbs/topics/ANSWERS/2003/ANS01187.html http://www.fds.gov/bbs/topics/ANSWERS/2003/ANS01187.html
38. United States Food and Drug Administration. FDA issues public health advisory on cautions for use of antidepressants in adults and children. FDA Talk Paper (Mar 2004). http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01283.html http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01283.html
39. Vorhees C.V., Acuff-Smith K.D., Schilling M.A., Fisher E., Moran M.S., and Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam. Appl. Toxicol. 23 (1994) 194-205
40. Waxman D.J., and O'Conner C. Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. 20 (2006) 2613-2629
41. Wegerer V., Moll G.H., Bagli M., Rothenberger A., Ruether E., and Huether G. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J. Child Adolesc. Psychopharmacol. 9 (1999) 13-24
42. Whitaker-Azmitia P. Role of serotonin and other neurotransmitter receptors in brain development: basis of developmental pharmacology. Pharmacol. Rev. 43 (1991) 553-561
43. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., and Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 (2004) 1341-1345
44. Williams J.W., Mulrow C.D., Chiquette E., Noel P.H., Aguilar C., and Cornell J. A systematic review of newer pharmacotherapies for depression in adults. Ann. Intern. Med. 132 (2000) 743-756
45. Wong D.T., Bymaster F.B., Reid L.R., and Threlkeld P.G. Fluoxetine and 2 other 5-HT reuptake inhibitors without affinity for neuronal receptors. Biochem. Pharmacol. 32 (1983) 1287-1293
46. Zito J.M., Safer D.J., Dos Reis S., Gardner J.F., Soeken K., Boles M., and Lynch F. Rising prevalence of antidepressants among US youths. Pediatrics 109 (2002) 721-727
47. Zito J.M., Safer D.J., Dos Reis S., Gardner J.F., Magder L., Soeken K., Boles M., Lynch F., and Riddle M.A. Psychotropic practice patterns for youth: a 10-year perspective. Arch. Pediatr. Adolesc. Med. 157 (2003) 17-25